

PUBLIC SUMMARY DOCUMENT

Product: Aquaflush ACE Stoma Stopper Dressing

Applicant: New Medical

Date of SPAP Meeting: 11 April 2016

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, New Medical, sought listing of the Aquaflush ACE Stoma Stopper Dressing, in subgroup 9(1) of the Stoma Appliance Scheme (SAS) Schedule. The product including two variants, was proposed at the unit price of \$4.532 with a maximum monthly quantity of 30 units.

2. Comparator

The applicant nominated AMSL Medicina Key-Hole Dressing (SAS code 9847G), which was listed in subgroup 9(1) of the SAS Schedule until 1 April 2016 as the comparator. This product was listed at a unit price of \$4.532, with a maximum monthly quantity of 30 units. This product required Stomal Therapy Nurse (STN) or Health Care Professional (HCP) authorisation prior to being supplied.

3. Background

This was the Stoma product Assessment Panel (SPAP)'s first consideration of this product.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a dressing for placing over a stoma stopper.

5. SPAP Comment

Clinical Analysis

The Panel noted that the proposed product is a hydrocolloid adhesive, absorbent and waterproof wound dressing. The Panel also noted that the proposed product is used to cover the Aquaflush ACE Stoma Stopper to prevent it from dislodging.

Economic Analysis

Not undertaken

Financial Analysis

As the comparator product is no longer listed on the SAS Schedule, this product is likely to be used as an alternative to the AMSL Medicina Ace 4cm silicone dressing. As this alternative dressing is listed at a lower price than that proposed by the applicant, listing the product would result in a cost to Government.

6. SPAP Recommendation

The SPAP recommended that the Aquaflush Ace Stoma Stopper Dressing, be listed in subgroup 9(1) of the SAS Schedule, at a unit price of \$4.532, with a maximum monthly quantity of 30 units. This product will also be classified with a R1 Restriction - requires Stomal Therapy Nurse (STN) or Health Care Professional (HCP) authorisation.

However, the Panel noted that all recommendations for products to be listed in Group 9 of the SAS Schedule may be subject to change as a result of the outcomes from the Group 9 Review.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

New Medical provided no comment on the SPAP recommendation.